Hubei
300966.SZHubei Goto Biopharm Co.,Ltd. Price (300966.SZ)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
115,025,074
(0.2185)%Income Statement Summary
| Revenue | |
| Cost of Revenue | |
| Gross Profit | |
| Operating Expenses | |
| Operating Income | |
| Other Expenses | |
| Net Income |
Income Statement
Hubei Goto Biopharm Co.,Ltd.Currency: CNY
| YEAR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||
| Revenue |
333,692,153.00
+0% |
437,301,668.00
+31% |
464,801,920.00
+6% |
468,117,263.00
+1% |
590,885,338.00
+26% |
604,571,473.00
+2% |
566,399,208.00
-6% |
||||||||||||
| Cost of Revenue | |||||||||||||||||||
| Cost of Revenue | 231,702,304.00 | 306,326,509.00 | 333,113,561.00 | 361,493,701.00 | 434,974,623.00 | 466,351,809.00 | 450,290,741.00 | ||||||||||||
| Gross Profit | |||||||||||||||||||
| Gross Profit |
101,989,849.00
+0% |
130,975,159.00
+28% |
131,688,359.00
+1% |
106,623,562.00
-19% |
155,910,715.00
+46% |
138,219,664.00
-11% |
116,108,467.00
-16% |
||||||||||||
| Gross Profit Ratio | (0.31%) | (0.30%) | (0.28%) | (0.23%) | (0.26%) | (0.23%) | (0.20%) | ||||||||||||
| Operating Expenses | |||||||||||||||||||
| Research and Development | 23,464,354.00 | 27,104,142.00 | 26,055,661.00 | 21,604,139.00 | 37,123,309.00 | 45,147,487.00 | 38,098,898.00 | ||||||||||||
| General and Administrative | -14,628,865.51 | -29,604,765.21 | -40,601,992.46 | -6,118,271.61 | 18,529,786.00 | 15,075,289.00 | 16,760,280.00 | ||||||||||||
| Selling, General & Admin... | -11,288,281.56 | -25,331,485.62 | -36,135,153.43 | -2,664,178.27 | 24,000,705.00 | 19,982,303.00 | 54,605,926.00 | ||||||||||||
| Selling & Marketing Exp... | 3,340,583.00 | 4,273,279.00 | 4,466,839.00 | 3,454,093.00 | 5,470,919.00 | 4,907,013.00 | 4,177,016.00 | ||||||||||||
| Depreciation and Amortiz... | 9,617,500.00 | 15,146,800.00 | 17,034,025.00 | 21,182,530.00 | 23,357,881.00 | 30,060,313.00 | 28,207,079.00 | ||||||||||||
| Other Expenses | 19,092,910.00 | 31,960,651.00 | 36,657,957.00 | 10,064,591.00 | 23,405,315.00 | -389,832.15 | 3,873,688.00 | ||||||||||||
| Total Operating Expenses | 39,988,109.00 | 44,293,185.00 | 38,842,546.00 | 40,704,664.00 | 83,473,445.00 | 85,289,675.00 | 96,578,512.00 | ||||||||||||
| Cost and Exponses | 271,690,414.00 | 350,619,695.00 | 371,956,108.00 | 402,198,366.00 | 518,448,068.00 | 551,641,485.00 | 546,869,253.00 | ||||||||||||
| Operating Income | |||||||||||||||||||
| Operating Income |
55,209,492.00
+0% |
78,332,937.00
+42% |
79,694,634.00
+2% |
57,300,022.00
-28% |
62,711,930.00
+9% |
38,903,531.00
-38% |
19,529,955.00
-50% |
||||||||||||
| Operating Income Ratio | (0.17%) | (0.18%) | (0.17%) | (0.12%) | (0.11%) | (0.06%) | (0.03%) | ||||||||||||
| Other Income and Exp... | |||||||||||||||||||
| Interest Income | 1,966,162.00 | 3,132,699.00 | 2,261,309.00 | 1,276,616.00 | 1,190,256.00 | 1,923,107.00 | 2,132,579.00 | ||||||||||||
| Interest Expenses | 19,257,307.00 | 23,972,910.00 | 23,344,861.00 | 13,501,455.00 | 5,174,333.00 | 13,372,459.00 | 13,552,176.00 | ||||||||||||
| Total Other Income/Exp... | 432,184.00 | 2,053,311.00 | 3,116,604.00 | 2,942,271.00 | 23,405,322.00 | -389,832.00 | -413,682.00 | ||||||||||||
| EBITDA | |||||||||||||||||||
| EBITDA | 69,110,657.00 | 100,327,676.00 | 104,766,849.00 | 88,175,552.00 | 116,390,208.00 | 79,117,085.00 | 60,505,063.00 | ||||||||||||
| EBITDA ratio | (0.26%) | (0.28%) | (0.28%) | (0.21%) | (0.20%) | (0.14%) | (0.11%) | ||||||||||||
| Income Before Tax | |||||||||||||||||||
| Income Before Tax | 55,641,676.00 | 80,386,248.00 | 82,811,238.00 | 60,242,293.00 | 86,117,245.00 | 38,513,699.00 | 19,116,273.00 | ||||||||||||
| Income Before Tax Ratio | (0.17%) | (0.18%) | (0.18%) | (0.13%) | (0.15%) | (0.06%) | (0.03%) | ||||||||||||
| Income Tax Expense | |||||||||||||||||||
| Income Tax Expense | 8,202,996.00 | 9,708,372.00 | 9,814,879.00 | 7,046,808.00 | 8,051,371.00 | -982,330.79 | -2,173,593.00 | ||||||||||||
| Net Income | |||||||||||||||||||
| Net Income | 47,438,680.00
+0% |
70,677,875.00
+49% |
72,996,358.00
+3% |
53,288,521.00
-27% |
78,330,635.00
+47% |
40,205,160.00
-49% |
23,005,014.00
-43% |
||||||||||||
| Net Income Ratio | (0.14%) | (0.16%) | (0.16%) | (0.11%) | (0.13%) | (0.07%) | (0.04%) | ||||||||||||
| Earning Per Share | |||||||||||||||||||
| Basic EPS | 1.03 | 0.84 | 0.63 | 0.46 | 0.68 | 0.35 | 0.20 | ||||||||||||
| Diluted EPS | 1.03 | 0.84 | 0.63 | 0.46 | 0.68 | 0.35 | 0.20 | ||||||||||||
| Share Outstanding | |||||||||||||||||||
| Basic Share Outstanding | 46,056,971.00 | 84,140,328.00 | 115,277,000.00 | 115,277,000.00 | 115,277,000.00 | 115,277,000.00 | 115,025,074.00 | ||||||||||||
| Diluted Share Outstanding | 46,056,971.00 | 84,140,328.00 | 115,277,000.00 | 115,277,000.00 | 115,277,000.00 | 115,277,000.00 | 115,025,074.00 | ||||||||||||